Scholarlink

Purpose <p>To clarify the characteristics of patients who received systemic therapy for recurrent hepatocellular carcinoma after liver resection and evaluate the associated prognostic factors.</p> Methods <p>We retrospectively analyzed data from 177 hepatocellular carcinoma patients with recurrence after liver resection; 79 received tyrosine kinase inhibitors or immune checkpoint inhibitors. Prognostic factors were analyzed in the patients who received systemic therapy.</p> Results <p>The median survival time after the initiation of systemic therapy was 23.3 months among the patients who received such therapy. These patients had more advanced disease at recurrence than those who did not receive systemic therapy. In the systemic therapy group, a deterioration of liver function relative to the preoperative status, expressed as the change in the albumin–bilirubin score (≥ 0.469 vs. &lt;0.469), was independently associated with a poorer survival (9.5 vs. 25.2 months, respectively; <i>P</i> = 0.022). Receiving multiple regimens was associated with a longer survival than receiving a single regimen (36.6 vs. 17.7 months, respectively; <i>P</i> = 0.023). Four patients (5.1%) achieved complete remission, two with systemic therapy alone and two after conversion therapy; all achieved a long-term overall survival.</p> Conclusions <p>A preserved liver function and multiple systemic therapy regimens are favorable prognostic factors. Achieving complete remission results in an improved long-term survival.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic significance of Albumin–Bilirubin score changes in patients treated with systemic therapy for recurrent hepatocellular carcinoma after liver resection

  • 期刊论文

  • 发表日期：

    2025年12月24日

查看全文
  • Yoh Asahi,
  • Tatsuhiko Kakisaka,
  • Tatsuya Orimo,
  • Shingo Shimada,
  • Akihisa Nagatsu,
  • Takeshi Aiyama,
  • Sunao Fujiyoshi,
  • Yuzuru Sakamoto,
  • Yuki Fujii,
  • Yuichi Yoshida,
  • Shunsuke Shichi,
  • Ken Imaizumi,
  • Akinobu Taketomi

摘要

Purpose

To clarify the characteristics of patients who received systemic therapy for recurrent hepatocellular carcinoma after liver resection and evaluate the associated prognostic factors.

Methods

We retrospectively analyzed data from 177 hepatocellular carcinoma patients with recurrence after liver resection; 79 received tyrosine kinase inhibitors or immune checkpoint inhibitors. Prognostic factors were analyzed in the patients who received systemic therapy.

Results

The median survival time after the initiation of systemic therapy was 23.3 months among the patients who received such therapy. These patients had more advanced disease at recurrence than those who did not receive systemic therapy. In the systemic therapy group, a deterioration of liver function relative to the preoperative status, expressed as the change in the albumin–bilirubin score (≥ 0.469 vs. <0.469), was independently associated with a poorer survival (9.5 vs. 25.2 months, respectively; P = 0.022). Receiving multiple regimens was associated with a longer survival than receiving a single regimen (36.6 vs. 17.7 months, respectively; P = 0.023). Four patients (5.1%) achieved complete remission, two with systemic therapy alone and two after conversion therapy; all achieved a long-term overall survival.

Conclusions

A preserved liver function and multiple systemic therapy regimens are favorable prognostic factors. Achieving complete remission results in an improved long-term survival.